Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury

Liver International

Volumn 37, Issue 1, 2017, Pages 132-140

  Mikus, Maria ^a   Drobin, Kimi ^a   Gry, Marcus ^b   Bachmann, Julie ^a   Lindberg, Johan ^b   Yimer, Getnet ^c   Aklillu, Eleni ^d   Makonnen, Eyasu ^c   Aderaye, Getachew ^c   Roach, James ^e   Fier, Ian ^e   Kampf, Caroline ^f   Göpfert, Jens ^g   Perazzo, Hugo ^h   Poynard, Thierry ^h   Stephens, Camilla ⁱ   Andrade, Raúl J ⁱ   Lucena, M Isabel ⁱ   Arber, Nadir ^j   Uhlén, Mathias ^a   Watkins, Paul B ^k   Schwenk, Jochen M ^a   Nilsson, Peter ^a   Schuppe Koistinen, Ina ^d,l   more..

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Momenta Pharmaceuticals Inc   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ UNIVERSITY OF MÁLAGA   (Spain)

^j TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l SCIENCE FOR LIFE LABORATORY   (Sweden)

more..

Author keywords

affinity proteomics; biomarker discovery; drug induced liver injury; plasma profiling; suspension bead arrays

Indexed keywords

ALANINE AMINOTRANSFERASE; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; HEPARIN; PARACETAMOL; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; BIOLOGICAL MARKER; CADHERIN; FABP1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MAJOR CLINICAL STUDY; PATIENT; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; SCREENING TEST; TOXIC HEPATITIS; TUBERCULOSIS; ADULT; BLOOD; FEMALE; MALE; MIDDLE AGED; RISK FACTOR; YOUNG ADULT;

ACETAMINOPHEN; ADULT; ALANINE TRANSAMINASE; ANTIGENS, CD; BIOMARKERS; CADHERINS; CHEMICAL AND DRUG INDUCED LIVER INJURY; FATTY ACID-BINDING PROTEINS; FEMALE; HEPARIN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; RISK FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84977547750     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13174     Document Type: Article

References (29)

1. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489–99.
2. Lee WM. Drug-induced hepatotoxicity. New Engl J Med 2003; 349: 474–85.
3. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806–15.
4. Navarro VJ, Senior JR. Drug-related hepatotoxicity. New Engl J Med 2006; 354: 731–9.
5. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451–5.
6. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008; 48: 1680–9.
7. Bachmann J, Burte F, Pramana S, et al. Affinity proteomics reveals elevated muscle proteins in plasma of children with cerebral malaria. PLoS Pathog 2014; 10: e1004038.
8. Bystrom S, Ayoglu B, Haggmark A, et al. Affinity proteomic profiling of plasma, cerebrospinal fluid, and brain tissue within multiple sclerosis. J Proteome Res 2014; 13: 4607–19.
9. Matheis K, Laurie D, Andriamandroso C, et al. A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today 2011; 16: 600–8.
10. Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347: 1260419.
11. Harris ES, Nelson WJ. VE-cadherin: at the front, center, and sides of endothelial cell organization and function. Curr Opin Cell Biol 2010; 22: 651–8.
12. Navaratna D, Mcguire PG, Menicucci G, Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007; 56: 2380–7.
13. Soeki T, Tamura Y, Shinohara H, et al. Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circ J 2004; 68: 1–5.
14. Zhang RY, Liu YY, Li L, et al. Increased levels of soluble vascular endothelial cadherin are associated with poor outcome in severe sepsis. J Int Med Res 2010; 38: 1497–506.
15. Sidibe A, Mannic T, Arboleas M, et al. Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor alpha-induced VE-cadherin cleavage. Arthritis Rheum 2012; 64: 77–87.
16. Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta 2008; 1778: 794–809.
17. Herren B, Levkau B, Raines EW, Ross R. Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell 1998; 9: 1589–601.
18. Pelsers MM, Namiot Z, Kisielewski W, et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem 2003; 36: 529–35.
19. Negishi K, Noiri E, Doi K, et al. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am J Pathol 2009; 174: 1154–9.
20. Nielsen SE, Sugaya T, Hovind P, et al. Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010; 33: 1320–4.
21. Kawai A, Kusaka M, Kitagawa F, et al. Serum liver-type fatty acid-binding protein predicts recovery of graft function after kidney transplantation from donors after cardiac death. Clin Transplant 2014; 28: 749–54.
22. Pelsers MM, Morovat A, Alexander GJ, et al. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem 2002; 48: 2055–7.
23. Akbal E, Koklu S, Kocak E, et al. Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res 2013; 44: 34–8.
24. Van Den Broek MA, Bloemen JG, Dello SA, et al. Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery. J Hepatol 2011; 55: 337–45.
25. Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharm 2010; 245: 134–42.
26. Haunerland NH, Spener F. Fatty acid-binding proteins–insights from genetic manipulations. Prog Lipid Res 2004; 43: 328–49.
27. Van De Poll MC, Derikx JP, Buurman WA, et al. Liver manipulation causes hepatocyte injury and precedes systemic inflammation in patients undergoing liver resection. World J Surg 2007; 31: 2033–8.
28. Rafter I, Graberg T, Kotronen A, et al. Isoform-specific alanine aminotransferase measurement can distinguish hepatic from extrahepatic injury in humans. Int J Mol Med 2012; 30: 1241–9.
29. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008; 245: 194–205.